Josef Brüggen

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 1.5K citations · Full text

Molecular Pharmacology, Mutant Bcr-abl, Medicine +5

Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis

Karel Odink, Nico Cerletti, Josef Brüggen et al. · Nature · 1987 · 694 citations

Inflammation, Rheumatology, Rheumatoid Disorder +7

New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis

Guido Bold, Karl‐Heinz Altmann, J Frei et al. · Journal of Medicinal Chemistry · 2000 · 213 citations · Full text

Solid Tumor, Pharmacotherapy, Tumor Biology +20

Phenotypic dynamics of tumor progression in human malignant melanoma

Eva‐Bettina Bröcker, Ludwig Suter, Josef Brüggen et al. · International Journal of Cancer · 1985 · 169 citations

Tumor Immunology, Cancer Immunosurveillance, Skin Cancer +15

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Ellen Weisberg, Paul W. Manley, Werner Breitenstein et al. · Cancer Cell · 2005 · 105 citations · Full text

Molecular Pharmacology, Mutant Bcr-abl, Medicine +5